Is KOD or ALT more profitable?

Kodiak Sciences has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -273.23% -85.48% Altimmune -214,860.98% -31.41% -26.96%

Does the media refer more to KOD or ALT?

In the previous week, Kodiak Sciences had 4 more articles in the media than Altimmune. MarketBeat recorded 9 mentions for Kodiak Sciences and 5 mentions for Altimmune. Kodiak Sciences' average media sentiment score of 1.57 beat Altimmune's score of 0.78 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ALT or PHVS?

Altimmune has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Altimmune $40K 15,123.93 -$88.09M -$0.78 N/A Pharvaris N/A N/A -$198.79M -$3.05 N/A

Is ALT or PHVS more profitable?

Pharvaris has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Altimmune -214,860.98% -31.41% -26.96% Pharvaris N/A -61.40% -56.00%

Does the media refer more to ALT or PHVS?

In the previous week, Pharvaris had 4 more articles in the media than Altimmune. MarketBeat recorded 9 mentions for Pharvaris and 5 mentions for Altimmune. Pharvaris' average media sentiment score of 1.47 beat Altimmune's score of 0.78 indicating that Pharvaris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VERA or ALT?

In the previous week, Vera Therapeutics had 2 more articles in the media than Altimmune. MarketBeat recorded 7 mentions for Vera Therapeutics and 5 mentions for Altimmune. Vera Therapeutics' average media sentiment score of 0.89 beat Altimmune's score of 0.78 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor COAG or ALT?

In the previous week, Altimmune had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 5 mentions for Altimmune and 2 mentions for Hemab Therapeutics. Altimmune's average media sentiment score of 0.78 beat Hemab Therapeutics' score of 0.58 indicating that Altimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, KLRA or ALT?

Altimmune has higher revenue and earnings than Kailera Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kailera Therapeutics N/A N/A -$148.96M -$3.65 thousand N/A Altimmune $40K 15,123.93 -$88.09M -$0.78 N/A

Does the media favor KLRA or ALT?

In the previous week, Kailera Therapeutics had 1 more articles in the media than Altimmune. MarketBeat recorded 6 mentions for Kailera Therapeutics and 5 mentions for Altimmune. Altimmune's average media sentiment score of 0.78 beat Kailera Therapeutics' score of 0.14 indicating that Altimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Altimmune (ALT) Competitors

$3.11 -0.13 (-4.01%)

As of 08/28/2026 04:00 PM Eastern

Compare

ALT vs. KOD, PHVS, VERA, COAG, and KLRA

Should you buy Altimmune stock or one of its competitors? Altimmune's main competitors and comparable companies include Kodiak Sciences (KOD), Pharvaris (PHVS), Vera Therapeutics (VERA), Hemab Therapeutics (COAG), and Kailera Therapeutics (KLRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Altimmune compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Altimmune (NASDAQ:ALT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Kodiak Sciences currently has a consensus target price of $48.14, indicating a potential upside of 27.63%. Altimmune has a consensus target price of $14.33, indicating a potential upside of 360.88%. Given Altimmune's stronger consensus rating and higher probable upside, analysts clearly believe Altimmune is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Kodiak Sciences has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

In the previous week, Kodiak Sciences had 4 more articles in the media than Altimmune. MarketBeat recorded 9 mentions for Kodiak Sciences and 5 mentions for Altimmune. Kodiak Sciences' average media sentiment score of 1.57 beat Altimmune's score of 0.78 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Altimmune has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.19	N/A
Altimmune	$40K	15,123.93	-$88.09M	-$0.78	N/A

Kodiak Sciences has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-273.23%	-85.48%
Altimmune	-214,860.98%	-31.41%	-26.96%

Summary

Altimmune beats Kodiak Sciences on 8 of the 14 factors compared between the two stocks.

How does Altimmune compare to Pharvaris?

Altimmune (NASDAQ:ALT) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Pharvaris has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-31.41%	-26.96%
Pharvaris	N/A	-61.40%	-56.00%

Altimmune has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.31, meaning that its stock price is 331% less volatile than the broader market.

78.1% of Altimmune shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Pharvaris had 4 more articles in the media than Altimmune. MarketBeat recorded 9 mentions for Pharvaris and 5 mentions for Altimmune. Pharvaris' average media sentiment score of 1.47 beat Altimmune's score of 0.78 indicating that Pharvaris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Altimmune presently has a consensus price target of $14.33, indicating a potential upside of 360.88%. Pharvaris has a consensus price target of $51.08, indicating a potential upside of 44.61%. Given Altimmune's higher possible upside, research analysts clearly believe Altimmune is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Altimmune has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	15,123.93	-$88.09M	-$0.78	N/A
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

Summary

Altimmune beats Pharvaris on 9 of the 15 factors compared between the two stocks.

How does Altimmune compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Altimmune (NASDAQ:ALT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Vera Therapeutics had 2 more articles in the media than Altimmune. MarketBeat recorded 7 mentions for Vera Therapeutics and 5 mentions for Altimmune. Vera Therapeutics' average media sentiment score of 0.89 beat Altimmune's score of 0.78 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vera Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Altimmune has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A
Altimmune	$40K	15,123.93	-$88.09M	-$0.78	N/A

Vera Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-84.13%	-66.79%
Altimmune	-214,860.98%	-31.41%	-26.96%

Vera Therapeutics currently has a consensus price target of $81.15, suggesting a potential upside of 137.36%. Altimmune has a consensus price target of $14.33, suggesting a potential upside of 360.88%. Given Altimmune's higher possible upside, analysts clearly believe Altimmune is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Vera Therapeutics beats Altimmune on 9 of the 15 factors compared between the two stocks.

How does Altimmune compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Altimmune (NASDAQ:ALT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Hemab Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Hemab Therapeutics' return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Altimmune	-214,860.98%	-31.41%	-26.96%

78.1% of Altimmune shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Hemab Therapeutics presently has a consensus target price of $51.40, indicating a potential upside of 14.63%. Altimmune has a consensus target price of $14.33, indicating a potential upside of 360.88%. Given Altimmune's stronger consensus rating and higher possible upside, analysts plainly believe Altimmune is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Hemab Therapeutics has higher earnings, but lower revenue than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
Altimmune	$40K	15,123.93	-$88.09M	-$0.78	N/A

In the previous week, Altimmune had 3 more articles in the media than Hemab Therapeutics. MarketBeat recorded 5 mentions for Altimmune and 2 mentions for Hemab Therapeutics. Altimmune's average media sentiment score of 0.78 beat Hemab Therapeutics' score of 0.58 indicating that Altimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Altimmune beats Hemab Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Altimmune compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Altimmune (NASDAQ:ALT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Kailera Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Kailera Therapeutics' return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Altimmune	-214,860.98%	-31.41%	-26.96%

78.1% of Altimmune shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Altimmune has higher revenue and earnings than Kailera Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Altimmune	$40K	15,123.93	-$88.09M	-$0.78	N/A

In the previous week, Kailera Therapeutics had 1 more articles in the media than Altimmune. MarketBeat recorded 6 mentions for Kailera Therapeutics and 5 mentions for Altimmune. Altimmune's average media sentiment score of 0.78 beat Kailera Therapeutics' score of 0.14 indicating that Altimmune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kailera Therapeutics presently has a consensus target price of $42.75, suggesting a potential upside of 163.73%. Altimmune has a consensus target price of $14.33, suggesting a potential upside of 360.88%. Given Altimmune's higher possible upside, analysts plainly believe Altimmune is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Altimmune beats Kailera Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Altimmune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALT vs. The Competition

Export

Metric	Altimmune	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$604.95M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-3.99	11.62	273.16	25.45
Price / Sales	15,123.93	1,400.24	640.71	89.43
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	1.56	16.53	12.98	6.14
Net Income	-$88.09M	-$22.80M	$3.48B	$348.86M
7 Day Performance	N/A	-0.31%	0.13%	-0.80%
1 Month Performance	4.19%	9.80%	7.08%	4.13%
1 Year Performance	-18.80%	55.66%	24.67%	15.17%

Altimmune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALT Altimmune	2.6214 of 5 stars	$3.11 -4.0%	$14.33 +360.9%	-18.8%	$604.95M	$40K	N/A	50	Options Volume
KOD Kodiak Sciences	2.4588 of 5 stars	$37.22 -2.9%	$48.14 +29.3%	+317.3%	$2.41B	N/A	N/A	90	News Coverage
PHVS Pharvaris	3.9919 of 5 stars	$37.31 +2.9%	$51.08 +36.9%	+63.1%	$2.37B	N/A	N/A	30	Positive News Short Interest Increase
VERA Vera Therapeutics	3.0696 of 5 stars	$33.72 +4.5%	$81.15 +140.7%	+58.0%	$2.33B	N/A	N/A	40	Options Volume
COAG Hemab Therapeutics	3.0008 of 5 stars	$46.67 -5.1%	$51.40 +10.1%	N/A	$2.30B	N/A	N/A	72

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALT) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Altimmune (ALT) Competitors

ALT vs. KOD, PHVS, VERA, COAG, and KLRA

How does Altimmune compare to Kodiak Sciences?

Summary

How does Altimmune compare to Pharvaris?

Summary

How does Altimmune compare to Vera Therapeutics?

Summary

How does Altimmune compare to Hemab Therapeutics?

Summary

How does Altimmune compare to Kailera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT vs. The Competition

Altimmune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Altimmune (ALT) Competitors

ALT vs. KOD, PHVS, VERA, COAG, and KLRA

How does Altimmune compare to Kodiak Sciences?

Do institutionals and insiders hold more shares of KOD or ALT?

Do analysts rate KOD or ALT?

Which has more volatility and risk, KOD or ALT?

Does the media refer more to KOD or ALT?

Which has stronger valuation & earnings, KOD or ALT?

Is KOD or ALT more profitable?

Summary

How does Altimmune compare to Pharvaris?

Is ALT or PHVS more profitable?

Which has more volatility and risk, ALT or PHVS?

Do institutionals & insiders hold more shares of ALT or PHVS?

Does the media refer more to ALT or PHVS?

Do analysts recommend ALT or PHVS?

Which has stronger earnings & valuation, ALT or PHVS?

Summary

How does Altimmune compare to Vera Therapeutics?

Do institutionals and insiders have more ownership in VERA or ALT?

Does the media refer more to VERA or ALT?

Which has more volatility & risk, VERA or ALT?

Which has higher valuation and earnings, VERA or ALT?

Is VERA or ALT more profitable?

Do analysts prefer VERA or ALT?

Summary

How does Altimmune compare to Hemab Therapeutics?

Is COAG or ALT more profitable?

Do institutionals & insiders believe in COAG or ALT?

Do analysts rate COAG or ALT?

Which has stronger valuation & earnings, COAG or ALT?

Does the media favor COAG or ALT?

Summary

How does Altimmune compare to Kailera Therapeutics?

Is KLRA or ALT more profitable?

Do insiders and institutionals have more ownership in KLRA or ALT?

Which has better valuation and earnings, KLRA or ALT?

Does the media favor KLRA or ALT?

Do analysts prefer KLRA or ALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALT vs. The Competition

Altimmune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools